Cargando…

Complement inhibition by gram-positive pathogens: molecular mechanisms and therapeutic implications

The plasma proteins of the complement system are essential in the innate immune response against bacteria. Complement labels bacteria with opsonins to support phagocytosis and generates chemoattractants to attract phagocytes to the site of infection. In turn, bacterial human pathogens have evolved d...

Descripción completa

Detalles Bibliográficos
Autores principales: Laarman, Alexander, Milder, Fin, van Strijp, Jos, Rooijakkers, Suzan
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2832872/
https://www.ncbi.nlm.nih.gov/pubmed/20062962
http://dx.doi.org/10.1007/s00109-009-0572-y
_version_ 1782178347555487744
author Laarman, Alexander
Milder, Fin
van Strijp, Jos
Rooijakkers, Suzan
author_facet Laarman, Alexander
Milder, Fin
van Strijp, Jos
Rooijakkers, Suzan
author_sort Laarman, Alexander
collection PubMed
description The plasma proteins of the complement system are essential in the innate immune response against bacteria. Complement labels bacteria with opsonins to support phagocytosis and generates chemoattractants to attract phagocytes to the site of infection. In turn, bacterial human pathogens have evolved different strategies to specifically impair the complement response. Here, we review the large arsenal of complement inhibitors produced by the gram-positive pathogens Staphylococcus aureus and Group A Streptococcus. We discuss how these bacterial molecules provide us with new tools to treat both infectious and inflammatory disease conditions in humans.
format Text
id pubmed-2832872
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-28328722010-03-15 Complement inhibition by gram-positive pathogens: molecular mechanisms and therapeutic implications Laarman, Alexander Milder, Fin van Strijp, Jos Rooijakkers, Suzan J Mol Med (Berl) Review The plasma proteins of the complement system are essential in the innate immune response against bacteria. Complement labels bacteria with opsonins to support phagocytosis and generates chemoattractants to attract phagocytes to the site of infection. In turn, bacterial human pathogens have evolved different strategies to specifically impair the complement response. Here, we review the large arsenal of complement inhibitors produced by the gram-positive pathogens Staphylococcus aureus and Group A Streptococcus. We discuss how these bacterial molecules provide us with new tools to treat both infectious and inflammatory disease conditions in humans. Springer-Verlag 2010-01-09 2010 /pmc/articles/PMC2832872/ /pubmed/20062962 http://dx.doi.org/10.1007/s00109-009-0572-y Text en © The Author(s) 2010 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Review
Laarman, Alexander
Milder, Fin
van Strijp, Jos
Rooijakkers, Suzan
Complement inhibition by gram-positive pathogens: molecular mechanisms and therapeutic implications
title Complement inhibition by gram-positive pathogens: molecular mechanisms and therapeutic implications
title_full Complement inhibition by gram-positive pathogens: molecular mechanisms and therapeutic implications
title_fullStr Complement inhibition by gram-positive pathogens: molecular mechanisms and therapeutic implications
title_full_unstemmed Complement inhibition by gram-positive pathogens: molecular mechanisms and therapeutic implications
title_short Complement inhibition by gram-positive pathogens: molecular mechanisms and therapeutic implications
title_sort complement inhibition by gram-positive pathogens: molecular mechanisms and therapeutic implications
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2832872/
https://www.ncbi.nlm.nih.gov/pubmed/20062962
http://dx.doi.org/10.1007/s00109-009-0572-y
work_keys_str_mv AT laarmanalexander complementinhibitionbygrampositivepathogensmolecularmechanismsandtherapeuticimplications
AT milderfin complementinhibitionbygrampositivepathogensmolecularmechanismsandtherapeuticimplications
AT vanstrijpjos complementinhibitionbygrampositivepathogensmolecularmechanismsandtherapeuticimplications
AT rooijakkerssuzan complementinhibitionbygrampositivepathogensmolecularmechanismsandtherapeuticimplications